{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:50:51Z","timestamp":1783335051928,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04190-6","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:19:06Z","timestamp":1754583546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between glycated hemoglobin\/high-density lipoprotein ratio and nonalcoholic fatty liver disease in a U.S. nondiabetic population: a cross-sectional study based on NHANES 2017\u20132020 data"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaowei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"4","key":"4190_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4190_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/hep.30254","volume":"69","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the united States. Hepatology. 2019;69(2):564\u201372.","journal-title":"Hepatology"},{"issue":"4","key":"4190_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"10290","key":"4190_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"key":"4190_CR5","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4190_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","volume":"9","author":"JA Thomas","year":"2024","unstructured":"Thomas JA, Kendall BJ, El-Serag HB, Thrift AP, Macdonald GA. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024;9(2):159\u201369.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"4190_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14218\/JCTH.2020.00065","volume":"8","author":"S Altajar","year":"2020","unstructured":"Altajar S, Baffy G. Skeletal muscle dysfunction in the development and progression of nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2020;8(4):414\u201323.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"4190_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbcan.2018.11.005","volume":"1871","author":"K Chen","year":"2019","unstructured":"Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q. Advancing the Understanding of NAFLD to hepatocellular carcinoma development: from experimental models to humans. Biochim Biophys Acta Rev Cancer. 2019;1871(1):117\u201325.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"4190_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2337\/dci23-0040","volume":"47","author":"DB Sacks","year":"2024","unstructured":"Sacks DB, Kirkman MS, Little RR. Point-of-Care HbA1c in clinical practice: caveats and considerations for optimal use. Diabetes Care. 2024;47(7):1104\u201310.","journal-title":"Diabetes Care"},{"issue":"2","key":"4190_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccc.2018.11.010","volume":"35","author":"A Balintescu","year":"2019","unstructured":"Balintescu A, M\u00e5rtensson J. Hemoglobin A1c and permissive hyperglycemia in patients in the intensive care unit with diabetes. Crit Care Clin. 2019;35(2):289\u2013300.","journal-title":"Crit Care Clin"},{"issue":"21","key":"4190_CR11","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.devcel.2023.09.007","volume":"58","author":"S Hu","year":"2023","unstructured":"Hu S, Zhu Y, Zhao X, Li R, Shao G, Gong D, Hu C, Liu H, Xu K, Liu C, et al. Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice. Dev Cell. 2023;58(21):2326\u2013e23372325.","journal-title":"Dev Cell"},{"issue":"11","key":"4190_CR12","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/CIRCRESAHA.123.321563","volume":"132","author":"MF Linton","year":"2023","unstructured":"Linton MF, Yancey PG, Tao H, Davies SS. HDL function and atherosclerosis: reactive dicarbonyls as promising targets of therapy. Circ Res. 2023;132(11):1521\u201345.","journal-title":"Circ Res"},{"key":"4190_CR13","doi-asserted-by":"publisher","first-page":"101728","DOI":"10.1016\/j.molmet.2023.101728","volume":"73","author":"G Mocciaro","year":"2023","unstructured":"Mocciaro G, Allison M, Jenkins B, Azzu V, Huang-Doran I, Herrera-Marcos LV, Hall Z, Murgia A, Susan D, Frontini M, et al. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL). Mol Metab. 2023;73:101728.","journal-title":"Mol Metab"},{"issue":"1","key":"4190_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12967-023-04047-0","volume":"21","author":"S Lu","year":"2023","unstructured":"Lu S, Xie Q, Kuang M, Hu C, Li X, Yang H, Sheng G, Xie G, Zou Y. Lipid metabolism, BMI and the risk of nonalcoholic fatty liver disease in the general population: evidence from a mediation analysis. J Transl Med. 2023;21(1):192.","journal-title":"J Transl Med"},{"key":"4190_CR15","doi-asserted-by":"publisher","first-page":"1078652","DOI":"10.3389\/fendo.2022.1078652","volume":"13","author":"J Hou","year":"2022","unstructured":"Hou J, Liu Y, Deng Z, Sun J, Zhao M. Glycohemoglobin: A new warning strategy for non-alcoholic fatty liver disease: study from the NHANES 2017\u20132020. Front Endocrinol (Lausanne). 2022;13:1078652.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4190_CR16","doi-asserted-by":"publisher","first-page":"857110","DOI":"10.3389\/fendo.2022.857110","volume":"13","author":"R Xie","year":"2022","unstructured":"Xie R, Liu M. Relationship between Non-Alcoholic fatty liver disease and degree of hepatic steatosis and bone mineral density. Front Endocrinol (Lausanne). 2022;13:857110.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4190_CR17","doi-asserted-by":"publisher","first-page":"925690","DOI":"10.3389\/fimmu.2022.925690","volume":"13","author":"R Xie","year":"2022","unstructured":"Xie R, Xiao M, Li L, Ma N, Liu M, Huang X, Liu Q, Zhang Y. Association between SII and hepatic steatosis and liver fibrosis: a population-based study. Front Immunol. 2022;13:925690.","journal-title":"Front Immunol"},{"issue":"6","key":"4190_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, et al. Accuracy of fibroscan controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"issue":"1","key":"4190_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12902-022-01134-z","volume":"22","author":"Y Xie","year":"2022","unstructured":"Xie Y, Kong W, Wang X, Wu Z. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr Disord. 2022;22(1):220.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"4190_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clinre.2018.08.007","volume":"43","author":"C Yu","year":"2019","unstructured":"Yu C, Wang L, Xue H, Lin H, Li Y, Chan SO. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes. Clin Res Hepatol Gastroenterol. 2019;43(1):58\u201366.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"4190_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s13679-020-00375-0","volume":"9","author":"A Tsatsoulis","year":"2020","unstructured":"Tsatsoulis A, Paschou SA. Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences. Curr Obes Rep. 2020;9(2):109\u201320.","journal-title":"Curr Obes Rep"},{"issue":"1","key":"4190_CR22","doi-asserted-by":"publisher","first-page":"15958","DOI":"10.1038\/s41598-023-43028-7","volume":"13","author":"J Huang","year":"2023","unstructured":"Huang J, Gao T, Zhang H, Wang X. Association of obesity profiles and metabolic health status with liver injury among US adult population in NHANES 1999\u20132016. Sci Rep. 2023;13(1):15958.","journal-title":"Sci Rep"},{"issue":"1","key":"4190_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12876-024-03362-0","volume":"24","author":"S He","year":"2024","unstructured":"He S, Lu S, Yu C, Kuang M, Qiu J, Sheng G, Zou Y. The newly proposed plasma-glycosylated hemoglobin A1c\/High-Density lipoprotein cholesterol ratio serves as a simple and practical indicator for screening metabolic associated fatty liver disease: an observational study based on a physical examination population. BMC Gastroenterol. 2024;24(1):274.","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"4190_CR24","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119(9):1787\u201398.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"4190_CR25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"EASL-EASD-EASO","year":"2016","unstructured":"EASL-EASD-EASO. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402.","journal-title":"J Hepatol"},{"issue":"4","key":"4190_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41569-020-00465-5","volume":"18","author":"ACT Ng","year":"2021","unstructured":"Ng ACT, Delgado V, Borlaug BA, Bax JJ. Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. Nat Rev Cardiol. 2021;18(4):291\u2013304.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"4190_CR27","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, et al. Insulin resistance drives hepatic de Novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130(3):1453\u201360.","journal-title":"J Clin Invest"},{"key":"4190_CR28","doi-asserted-by":"crossref","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8).","DOI":"10.3390\/ijms22084156"},{"issue":"8","key":"4190_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","volume":"65","author":"M Mota","year":"2016","unstructured":"Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1049\u201361.","journal-title":"Metabolism"},{"issue":"9","key":"4190_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/apt.17397","volume":"57","author":"CE Fu","year":"2023","unstructured":"Fu CE, Yong JN, Ng CH, Nah B, Chew NWS, Chin YH, Kong G, Tan DJH, Lim WH, Lim LKE, et al. The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Aliment Pharmacol Ther. 2023;57(9):979\u201387.","journal-title":"Aliment Pharmacol Ther"},{"key":"4190_CR31","doi-asserted-by":"crossref","unstructured":"Stadler JT, Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function. Int J Mol Sci 2020, 21(23).","DOI":"10.3390\/ijms21238985"},{"issue":"1","key":"4190_CR32","doi-asserted-by":"publisher","first-page":"100627","DOI":"10.1016\/j.jhepr.2022.100627","volume":"5","author":"L Crudele","year":"2023","unstructured":"Crudele L, De Matteis C, Piccinin E, Gadaleta RM, Cariello M, Di Buduo E, Piazzolla G, Suppressa P, Berardi E, Sabb\u00e0 C, et al. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. JHEP Rep. 2023;5(1):100627.","journal-title":"JHEP Rep"},{"issue":"12","key":"4190_CR33","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","volume":"33","author":"L Camont","year":"2013","unstructured":"Camont L, Lhomme M, Rached F, Le Goff W, N\u00e8gre-Salvayre A, Salvayre R, Calzada C, Lagarde M, Chapman MJ, Kontush A. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol. 2013;33(12):2715\u201323.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"4190_CR34","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.26226","volume":"58","author":"K Begriche","year":"2013","unstructured":"Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58(4):1497\u2013507.","journal-title":"Hepatology"},{"issue":"1","key":"4190_CR35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s40001-023-01369-z","volume":"28","author":"J Jin","year":"2023","unstructured":"Jin J, Hu X, Francois M, Zeng P, Wang W, Yu B, Zhou Y, Dong H. Association between remnant cholesterol, metabolic syndrome, and cardiovascular disease: post hoc analysis of a prospective National cohort study. Eur J Med Res. 2023;28(1):420.","journal-title":"Eur J Med Res"},{"key":"4190_CR36","doi-asserted-by":"crossref","unstructured":"Jia G, Hill MA, Sowers JR. Vascular endothelial mineralocorticoid receptors and epithelial sodium channels in metabolic syndrome and related cardiovascular disease. J Mol Endocrinol. 2023;71(3).","DOI":"10.1530\/JME-23-0066"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04190-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04190-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04190-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:53:54Z","timestamp":1757354034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04190-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4190"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04190-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The portions of this study involving human participants, human materials, or human data were conducted in accordance with the Declaration of Helsinki and were approved by the NCHS Ethics Review Board. The patients\/participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"567"}}